Somaxon Pharmaceuticals — UBS Global Life Science Conference 2010
22 slides from Somaxon Pharmaceuticals's conference presentation, Sep 21, 2010
Slide 1: UBS Global Life Science Conference
UBS Global Life Science Conference September 21, 2010 NASDAQ: SOMX
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about our business, including our commercialization timeline, plans and outlook, future financial results and events that have not yet occurred. Operating in the pharmaceutical industry inherently involves significant r
Slide 3: Executing Our Strategy
Executing Our Strategy 3 In-license Clinic Drug development 2 Phase II, 4 Phase III Studies NDA Filing, FDA Approval Established co-promote partnership Launched Silenor for insomnia Specialty Pharma Company 3Q 2010 3Q 2010 1Q 2010 2006 2003
Slide 4: Investment Attributes
Investment Attributes Streamlined specialty pharmaceutical companyCentral nervous system therapeuticsFocused on high value branded pharmaceuticalsEstablished commercial organizationFocused on specialty marketsManagement with deep commercial expertiseSilenor: Highly differentiated product, meaningful
Slide 5: Silenor for Insomnia
Silenor for Insomnia 5 H1 antagonist1,2 Supports 7-8 hours of sleep3 No next-day residual effects in most patients No evidence of rebound insomnia or tolerance1,3 Adverse-event profilecomparable to placebo1,3 Helps patients reach their sleep maintenance goal As demonstrated by standard psychomotor t
Slide 6: Insomnia Market Dynamics
Insomnia Market Dynamics U.S. market under-diagnosed and under-treated70 million estimated to suffer from insomnia 14 million (20%) are currently on Rx treatmentAssociated with high costs and multiple adverse events1,2,3Annual direct and indirect costs: May be as high as $92.5 - $107.5 billionEstima
Slide 7: Market Insights
Market Insights Physician InsightsInsomnia is a complicated, widespread and ever-increasing problem Agree that final 1/3 of night's sleep is importantClinical experience dictates product perceptions, more than data"My patients will tell me if it is effective or not"Patient InsightsInsomnia described
Slide 8: Primary Issue: Sleep Maintenance
Primary Issue: Sleep Maintenance 8 Silenor addresses the two most common complaints Source: National Sleep Foundation. Summary of findings: 2008 Sleep in America poll. n = 1760 respondents. Maintenance Onset Difficulty Falling Asleep 64% of patients polled had sleep problems... Frequent Nocturnal Aw
Slide 9: Large and Accessible Market
Large and Accessible Market $2 billion in U.S. sales in 2009Over 67 million U.S. TRx's written in 2009Concentrated market~44,000 doctors write half the TRx's30% of highest prescribing doctors are specialistsTop decile prescribers average >1,000 Rx's /yearSolid "window of opportunity" for new treatme
Slide 10: Silenor Commercial Strategy
Silenor Commercial Strategy 10 Target high-prescribing physiciansSomaxon sales force targets 18K specialistsP&G sales force targets 17K PCPsCombined effort reaches 40% of prescription market Deploy comprehensive promotional/marketing campaignTargeting physicians and consumers Drive patient access in
Slide 11: Strategic Partnership
Strategic Partnership Leverages P&G's highly regarded and tenured professional health care sales forcePrimary details for Silenor to physicians and pharmacistsEnables Somaxon to retain significant economic and long-term control of SilenorLife-cycle management: P&G has right of first negotiation to d
Slide 12: Co-Promotion Structure
Co-Promotion Structure 12 Sales force of 110Focused on specialistsLeading marketing effortManufacture and distribute productBook all revenues Sales force of 105Receives fixed fee and royalty on U.S. net salesFocused on primary care physiciansTargeting 25K pharmacies at launchProvide supplemental man
Slide 13: Compelling Brand Message
Compelling Brand Message Brand Identity Positioning Key Messages Silenor is the first-line therapy for sleep maintenance insomnia Refreshingly Different A full 7-8 hours of sleepSafe for chronic useNon-addicting, no abuse potentialPlacebo-like side effect profileNo meaningful hangover effectUnique M
Slide 14: Professional Campaign
Professional Campaign Integrated marketing campaign to 35K high value physiciansHigh impact brand awareness programs Supportive sales aids and branded marketing materialsNon-personal promotion to reach non-called-on prescribersWeb-based and media initiatives to reach prescribers25K targeted pharmacy
Slide 15: Comprehensive Branding
Comprehensive Branding 15
Slide 16: Direct to Insomniac Campaign
Direct to Insomniac Campaign Internet rivals traditional DTC ads for Rx info by consumers before seeing MD1Consumers seek insomnia info in general before searching for specific medications1Physicians remain the most important source of Rx educationInternet a close second2 Physician internet use repl
Slide 17: Direct to Insomniac Campaign: Multi-faceted Outreach Strategy
Direct to Insomniac Campaign Multi-faceted Outreach Strategy Web property deploymentwww.silenor.com Outreach through Web MDSearch engine optimization ( , , etc.)Public Relations Build awareness of disease and Silenor brandPoint of Care - MD OfficeIn-office videoPatient brochurePoint of Care - Pharma
Slide 18: Managed Care Targeting
Managed Care Targeting Tier 3 at launch for majority of plansMinimize step edits and quantity limits3mg /6mg priced competitively at $151.50/packNormalize the cost to the patient through co-pay assistanceFirst Rx and two refillsConfigured to be delivered as physical part of the sampleOut of pocket e
Slide 19: Summary Information
Summary Information Cash, cash equivalents & marketable securities (6/30/10) eA Shares outstanding 35.1 MM Fully diluted shares 42.2MM Somaxon
Slide 20: Building the Enterprise
Building the Enterprise Successfully launch SilenorPotential for meaningful revenueEstablish commercial presenceExtend Silenor franchiseSecure additional IPLife cycle management for Rx productPotential for OTCLeverage existing commercial operationsConsider co-promote opportunitiesFocus on growthIn-l
Slide 21: Investment Attributes
Investment Attributes Streamlined specialty pharmaceutical companyCentral nervous system therapeuticsFocused on high value branded pharmaceuticalsEstablished commercial organizationFocused on specialty marketsManagement with deep commercial expertiseSilenor: Highly differentiated product, meaningful
Slide 22: Somaxon Pharmaceuticals
Somaxon Pharmaceuticals
Somaxon Pharmaceuticals — UBS Global Life Science Conference 2010 on 6ix